KR20220149519A - B형 및 d형 간염의 치료 및 예방을 위한 조성물 및 방법 - Google Patents
B형 및 d형 간염의 치료 및 예방을 위한 조성물 및 방법 Download PDFInfo
- Publication number
- KR20220149519A KR20220149519A KR1020227029043A KR20227029043A KR20220149519A KR 20220149519 A KR20220149519 A KR 20220149519A KR 1020227029043 A KR1020227029043 A KR 1020227029043A KR 20227029043 A KR20227029043 A KR 20227029043A KR 20220149519 A KR20220149519 A KR 20220149519A
- Authority
- KR
- South Korea
- Prior art keywords
- gly
- arg
- glu
- lys
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10111—Deltavirus, e.g. hepatitis delta virus
- C12N2760/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Beans For Foods Or Fodder (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966970P | 2020-01-28 | 2020-01-28 | |
| US62/966,970 | 2020-01-28 | ||
| PCT/US2021/015126 WO2021154752A1 (en) | 2020-01-28 | 2021-01-26 | Compositions and methods for treating and preventing hepatitis b and d |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220149519A true KR20220149519A (ko) | 2022-11-08 |
Family
ID=74673345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227029043A Pending KR20220149519A (ko) | 2020-01-28 | 2021-01-26 | B형 및 d형 간염의 치료 및 예방을 위한 조성물 및 방법 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230079898A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4096711A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7855515B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220149519A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115335075A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021214939A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3169407A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022009169A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021154752A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101564533B (zh) * | 2009-06-12 | 2012-01-04 | 东南大学 | 戊型肝炎蛋白-核酸复合疫苗及其制备方法 |
| CN102895659B (zh) * | 2011-07-29 | 2014-10-29 | 复旦大学 | 一种防治老年痴呆症复合疫苗及其制备方法 |
| US10905760B2 (en) | 2016-01-28 | 2021-02-02 | Svenska Vaccinfabriken Produktion Ab | Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes |
| AU2017332854B2 (en) * | 2016-09-21 | 2024-11-14 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
-
2021
- 2021-01-26 CN CN202180022581.7A patent/CN115335075A/zh active Pending
- 2021-01-26 WO PCT/US2021/015126 patent/WO2021154752A1/en not_active Ceased
- 2021-01-26 US US17/794,786 patent/US20230079898A1/en not_active Abandoned
- 2021-01-26 EP EP21707475.6A patent/EP4096711A1/en active Pending
- 2021-01-26 AU AU2021214939A patent/AU2021214939A1/en active Pending
- 2021-01-26 MX MX2022009169A patent/MX2022009169A/es unknown
- 2021-01-26 JP JP2022546448A patent/JP7855515B2/ja active Active
- 2021-01-26 CA CA3169407A patent/CA3169407A1/en active Pending
- 2021-01-26 KR KR1020227029043A patent/KR20220149519A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7855515B2 (ja) | 2026-05-08 |
| AU2021214939A1 (en) | 2022-09-15 |
| CN115335075A (zh) | 2022-11-11 |
| JP2023512526A (ja) | 2023-03-27 |
| CA3169407A1 (en) | 2021-08-05 |
| EP4096711A1 (en) | 2022-12-07 |
| US20230079898A1 (en) | 2023-03-16 |
| WO2021154752A1 (en) | 2021-08-05 |
| MX2022009169A (es) | 2022-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019202515B2 (en) | Vaccine composition | |
| KR102286397B1 (ko) | 신규 백신 면역보조제 | |
| CN111533812B (zh) | 针对sars-cov-2病毒的dna疫苗及其用途 | |
| KR20200101416A (ko) | B형 간염 바이러스(hbv) 백신 및 그 용도 | |
| EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
| KR20230015914A (ko) | 캡핑 화합물, 조성물 및 이의 사용 방법 | |
| US20190083607A1 (en) | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes | |
| JP2025179041A (ja) | 帯状疱疹mRNAワクチン及びその調製方法と使用 | |
| KR20220042116A (ko) | B형 간염 바이러스(HBV) 백신 및 HBV-타케팅 RNAi의 조합 | |
| CN115335390A (zh) | 基于SARS-CoV-2的S蛋白的疫苗和组合物 | |
| CN115666634A (zh) | 用于治疗和预防冠状病毒的组合物和方法 | |
| CZ20011521A3 (cs) | Farmaceutický prostředek obsahující fragmenty DNA kódující antigenní protein vykazující protinádorový účinek | |
| RU2812764C1 (ru) | Композиции и способы для лечения и предотвращения гепатита в и d | |
| CN114340663A (zh) | 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合 | |
| CN115335075A (zh) | 治疗和预防乙型肝炎和丁型肝炎的组合物和方法 | |
| HK40083708A (en) | Compositions and methods for treating and preventing hepatitis b and d | |
| JP2024516882A (ja) | 構築物と免疫刺激性化合物の共発現 | |
| KR20240087649A (ko) | B형 및 d형 간염의 치료 및 예방을 위한 조성물 및 방법 | |
| KR20220041079A (ko) | B형 간염 바이러스(hbv) 백신 및 항-pd-1 항체의 조합 | |
| KR20210084125A (ko) | 신규 사이토메갈로바이러스 dna 백신 컨스트럭트 및 그의 용도 | |
| HK40037585A (en) | Novel vaccine adjuvant | |
| JP2026022933A (ja) | B型肝炎ウイルスワクチン | |
| JPWO2005090576A1 (ja) | 百日咳感染症予防用dna構築物 | |
| HK1165694B (en) | Codon-optimized hepatitis b virus core antigen (hbcag) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |